Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 18.34M
March 31, 2026 22.48M
December 31, 2025 23.71M
September 30, 2025 84.28M
June 30, 2025 55.38M
March 31, 2025 56.46M
December 31, 2024 57.80M
September 30, 2024 70.05M
June 30, 2024 70.80M
March 31, 2024 77.86M
December 31, 2023 3.603M
September 30, 2023 3.279M
June 30, 2023 0.882M
March 31, 2023 2.713M
December 31, 2022 2.742M
September 30, 2022 -2.28M
June 30, 2022 -14.19M
March 31, 2022 -9.240M
December 31, 2021 -7.822M
September 30, 2021 -6.97M
June 30, 2021 7.037M
March 31, 2021 14.40M
Date Value
December 31, 2020 -2.641M
September 30, 2020 14.07M
June 30, 2020 -0.7974M
March 31, 2020 3.041M
December 31, 2019 4.617M
September 30, 2019 3.202M
June 30, 2019 2.948M
March 31, 2019 2.713M
December 31, 2018 4.474M
September 30, 2018 5.532M
June 30, 2018 7.628M
March 31, 2018 1.098M
December 31, 2017 2.732M
September 30, 2017 2.796M
June 30, 2017 4.645M
March 31, 2017 1.471M
December 31, 2016 3.213M
September 30, 2016 -12.37M
June 30, 2016 -9.235M
March 31, 2016 -5.420M
December 31, 2015 -3.630M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.387B
Alnylam Pharmaceuticals, Inc. 3.604B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics